ATM基因改变与177Lu-PSMA-617治疗转移性去势抵抗性前列腺癌疗效的关联
该回顾性基因组研究纳入205例接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者,发现ATM改变与更高的PSA50应答率、更长PFS和OS独立相关,而CDK12改变是最强的不良基因组因素;汇总分析进一步验证ATM改变与改善OS相关。
要点
- ATM改变与177Lu-PSMA-617治疗后PSA50应答、PFS和OS改善独立相关。
- CDK12改变与显著缩短的PFS和OS相关,为最强不良基因组因素。
- BRCA2改变与临床结局无显著关联,HRR基因间存在明显异质性。
核心结论
- ATM改变与177Lu-PSMA-617治疗后改善的临床结局独立相关,并在汇总分析中得到验证。
- HRR基因间存在显著异质性,支持基因层面而非复合HRR分析用于精准肿瘤学。
研究设计与样本
- 回顾性基因组研究纳入205例2022至2026年在明尼苏达大学接受177Lu-PSMA-617治疗且具备下一代DNA测序结果的转移性去势抵抗性前列腺癌患者。
- 终点包括PSA应答(较基线降低至少50%[PSA50])、无进展生存期(PFS)和总生存期(OS)。
- 对已发表研究中按ATM、TP53、CDK12、SPOP和AR改变状态报告OS风险比的研究进行随机效应汇总分析。
主要发现
- ATM改变(12.7%)与改善的PSA50应答独立相关(比值比2.91;P=0.009)。
- ATM改变与更长的PFS(风险比0.40;P=0.002)和更长的OS(风险比0.39;P=0.003)独立相关。
- BRCA2改变与临床结局无显著关联。
- CDK12改变与显著缩短的PFS(风险比2.76;P=0.013)和OS(风险比2.58;P=0.016)相关。
- 汇总分析中ATM改变仍与改善的OS显著相关(汇总风险比0.36),TP53(汇总风险比1.49)和AR(汇总风险比1.57)与显著更差的OS相关。
关键数值与推荐
- PSA50应答定义为前列腺特异性抗原较基线降低至少50%。
- ATM改变与改善PSA50应答的比值比为2.91(P=0.009)。
- ATM改变与PFS的风险比为0.40(P=0.002),与OS的风险比为0.39(P=0.003)。
- CDK12改变与PFS的风险比为2.76(P=0.013),与OS的风险比为2.58(P=0.016)。
- 汇总分析中ATM改变的汇总OS风险比为0.36,TP53为1.49,AR为1.57。
临床怎么用
- 对于接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者,ATM改变可能提示更好的治疗应答和生存结局。
- CDK12改变可能提示较差的PFS和OS,有助于风险分层和治疗决策。
- 建议采用基因层面而非复合HRR分析来评估HRR基因改变对放射性药物治疗预后的影响。
局限性
- 本研究为单中心回顾性研究,样本量205例,可能存在选择偏倚。
- 汇总分析基于已发表研究,可能存在异质性和发表偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment with 177Lu-PSMA-617 improves survival in some patients with metastatic castration-resistant prostate cancer, yet marked heterogeneity in treatment response underscores the need for robust biomarkers. Homologous recombination repair (HRR) gene alterations are frequently analyzed in composite, potentially obscuring gene-level predictive signals. Methods: We conducted a retrospective genomic study of 205 patients with metastatic castration-resistant prostate cancer who received 177Lu-PSMA-617 at the University of Minnesota between 2022 and 2026 and for whom next-generation DNA sequencing results were available. Clinical endpoints included a prostate-specific antigen (PSA) response (a reduction of at least 50% from baseline [PSA50]), progression-free survival (PFS), and overall survival (OS). A random-effects pooled analysis of published studies reporting OS hazard ratios according to ATM, TP53, CDK12, SPOP, and AR alteration status was also performed. Results: ATM alterations (12.7%) were independently associated with improved PSA50 response (odds ratio, 2.91; P = 0.009), longer PFS (hazard ratio [HR], 0.40; P = 0.002), and longer OS (HR, 0.39; P = 0.003). BRCA2 alterations were not associated with clinical outcomes. CDK12 alterations represented the strongest adverse genomic factor, conferring significantly shorter PFS (HR, 2.76; P = 0.013) and OS (HR, 2.58; P = 0.016). In the pooled analysis, ATM alterations remained significantly associated with improved OS (pooled HR, 0.36), whereas TP53 (pooled HR, 1.49) and AR (pooled HR, 1.57) were associated with significantly worse OS. Conclusion: ATM alterations were independently associated with improved outcomes after treatment with 177Lu-PSMA-617 and validated across a pooled analysis. Marked heterogeneity among individual HRR genes was observed, supporting gene-level rather than composite HRR analysis for precision oncology in radiopharmaceutical therapy.
引用
- Mahajan V, Yu L, Kollitz L, et al. Association of ATM Alterations with Outcomes After 177Lu-PSMA-617 Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2026. PMID: 42785951. doi:10.2967/jnumed.126.273055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。